Challengers Eye a Piece of EpiPen Market as Pricing Scandal Engulfs Mylan

Source: FiercePharma

Tuesday, August 30, 2016 | Health Care , Imprimis Pharmaceuticals


Amid a tidal wave of backlash from politicians, media, consumers and others over its prices for EpiPen, Mylan Monday said it would roll out a generic copy of the star product. But other products are aiming to hit the market--and they could trigger real competition in a field where Mylan has been playing solo.

Open in New Window

Comments

You must be logged in to leave a comment.